Identification of patients at high risk of secondary
extramedullary multiple myeloma development

J 2022

Identification of patients at high risk of secondary extramedullary multiple myeloma development

ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Jiri MINARIK, Petra KRHOVSKA, Jakub RADOCHA et. al.

Basic information

Original name

Identification of patients at high risk of secondary extramedullary multiple myeloma development

Authors

ŠTORK, Martin (203 Czech Republic), Sabina ŠEVČÍKOVÁ (203 Czech Republic, guarantor, belonging to the institution), Jiri MINARIK (203 Czech Republic), Petra KRHOVSKA (203 Czech Republic), Jakub RADOCHA (203 Czech Republic), Lenka POSPISILOVA (203 Czech Republic), Lucie KUBÍNOVÁ (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic), Ivan SPICKA (203 Czech Republic), Jan STRAUB (203 Czech Republic), Petr PAVLICEK (203 Czech Republic), Alexandra JUNGOVA (203 Czech Republic), Tomas JELINEK (203 Czech Republic), Viera SANDECKÁ (703 Slovakia), Vladimir MAISNAR (203 Czech Republic), Roman HAJEK (203 Czech Republic) and Luděk POUR (203 Czech Republic)

Edition

British journal of haematology, England, Wiley-Blackwell, 2022, 0007-1048

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 6.500

RIV identification code

RIV/00216224:14110/22:00129658

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1111/bjh.17925

UT WoS

000713664200001

Keywords in English

multiple myeloma; extramedullary disease; prognostic factors

Abstract

V originále

Multiple myeloma (MM) is characterized by malignant plasma cell infiltration of the bone marrow. In extramedullary multiple myeloma (EMD), a subclone of these cells migrates out of the bone marrow. Out of 4 985 MM patients diagnosed between 2005 and 2017 in the Czech Republic, we analyzed 234 secondary EMD patients to clarify risk factors of secondary EMD development. We found younger age [<65 years; odds ratio (OR) 4 center dot 38, 95% confidence interval (CI): 2 center dot 46-7 center dot 80, P < 0 center dot 0001], high lactate dehydrogenase (LDH) levels (>5 mu kat/l; OR 2 center dot 07, 95% CI: 1 center dot 51-2 center dot 84, P < 0 center dot 0001), extensive osteolytic activity (OR 2 center dot 21, 95% CI: 1 center dot 54-3 center dot 15, P < 0 center dot 001), and immunoglobulin A (IgA; OR 1 center dot 53, 95% CI: 1 center dot 11-2 center dot 11, P = 0 center dot 009) or the non-secretory type of MM (OR 2 center dot 83; 95% CI: 1 center dot 32-6 center dot 04, P = 0 center dot 007) at the time of MM diagnosis to be the main risk factors for secondary EMD development. Newly diagnosed MM (NDMM) patients with subsequent EMD had inferior median progression-free (PFS) and overall (OS) survival when compared to NDMM patients without future EMD [mPFS: 13 center dot 8 months (95% CI: 11 center dot 4-16 center dot 3) vs 18 center dot 8 months (95% CI: 17 center dot 7-19 center dot 9), P = 0 center dot 006; mOS: 26 center dot 7 months (95% CI: 18 center dot 1-35 center dot 4) vs 58 center dot 7 months (95% CI: 54 center dot 8-62 center dot 6), P < 0 center dot 001]. We found that NDMM patients with specific risk factors associated with secondary EMD development have a more aggressive disease course before secondary EMD develops.

Links

NV17-29343A, research and development project

Name: Analýza mikroprostředí kostní dřeně u extramedulárního relapsu mnohočetného myelomu

Citovat

ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Jiri MINARIK, Petra KRHOVSKA, Jakub RADOCHA, Lenka POSPISILOVA, Lucie KUBÍNOVÁ, Jiří JARKOVSKÝ, Ivan SPICKA, Jan STRAUB, Petr PAVLICEK, Alexandra JUNGOVA, Tomas JELINEK, Viera SANDECKÁ, Vladimir MAISNAR, Roman HAJEK and Luděk POUR. Identification of patients at high risk of secondary extramedullary multiple myeloma development. British journal of haematology. England: Wiley-Blackwell, 2022, vol. 196, No 4, p. 954-962. ISSN 0007-1048. Available from: https://dx.doi.org/10.1111/bjh.17925.

@article{1818677,
   author = {Štork, Martin and Ševčíková, Sabina and Minarik, Jiri and Krhovska, Petra and Radocha, Jakub and Pospisilova, Lenka and Kubínová, Lucie and Jarkovský, Jiří and Spicka, Ivan and Straub, Jan and Pavlicek, Petr and Jungova, Alexandra and Jelinek, Tomas and Sandecká, Viera and Maisnar, Vladimir and Hajek, Roman and Pour, Luděk},
   article_location = {England},
   article_number = {4},
   doi = {http://dx.doi.org/10.1111/bjh.17925},
   keywords = {multiple myeloma; extramedullary disease; prognostic factors},
   language = {eng},
   issn = {0007-1048},
   journal = {British journal of haematology},
   title = {Identification of patients at high risk of secondary extramedullary multiple myeloma development},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/bjh.17925},
   volume = {196},
   year = {2022}
}

TY  - JOUR
ID  - 1818677
AU  - Štork, Martin - Ševčíková, Sabina - Minarik, Jiri - Krhovska, Petra - Radocha, Jakub - Pospisilova, Lenka - Kubínová, Lucie - Jarkovský, Jiří - Spicka, Ivan - Straub, Jan - Pavlicek, Petr - Jungova, Alexandra - Jelinek, Tomas - Sandecká, Viera - Maisnar, Vladimir - Hajek, Roman - Pour, Luděk
PY  - 2022
TI  - Identification of patients at high risk of secondary extramedullary multiple myeloma development
JF  - British journal of haematology
VL  - 196
IS  - 4
SP  - 954-962
EP  - 954-962
PB  - Wiley-Blackwell
SN  - 00071048
KW  - multiple myeloma
KW  - extramedullary disease
KW  - prognostic factors
UR  - https://onlinelibrary.wiley.com/doi/10.1111/bjh.17925
N2  - Multiple myeloma (MM) is characterized by malignant plasma cell infiltration of the bone marrow. In extramedullary multiple myeloma (EMD), a subclone of these cells migrates out of the bone marrow. Out of 4 985 MM patients diagnosed between 2005 and 2017 in the Czech Republic, we analyzed 234 secondary EMD patients to clarify risk factors of secondary EMD development. We found younger age [<65 years; odds ratio (OR) 4 center dot 38, 95% confidence interval (CI): 2 center dot 46-7 center dot 80, P < 0 center dot 0001], high lactate dehydrogenase (LDH) levels (>5 mu kat/l; OR 2 center dot 07, 95% CI: 1 center dot 51-2 center dot 84, P < 0 center dot 0001), extensive osteolytic activity (OR 2 center dot 21, 95% CI: 1 center dot 54-3 center dot 15, P < 0 center dot 001), and immunoglobulin A (IgA; OR 1 center dot 53, 95% CI: 1 center dot 11-2 center dot 11, P = 0 center dot 009) or the non-secretory type of MM (OR 2 center dot 83; 95% CI: 1 center dot 32-6 center dot 04, P = 0 center dot 007) at the time of MM diagnosis to be the main risk factors for secondary EMD development. Newly diagnosed MM (NDMM) patients with subsequent EMD had inferior median progression-free (PFS) and overall (OS) survival when compared to NDMM patients without future EMD [mPFS: 13 center dot 8 months (95% CI: 11 center dot 4-16 center dot 3) vs 18 center dot 8 months (95% CI: 17 center dot 7-19 center dot 9), P = 0 center dot 006; mOS: 26 center dot 7 months (95% CI: 18 center dot 1-35 center dot 4) vs 58 center dot 7 months (95% CI: 54 center dot 8-62 center dot 6), P < 0 center dot 001]. We found that NDMM patients with specific risk factors associated with secondary EMD development have a more aggressive disease course before secondary EMD develops.
ER  -

ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Jiri MINARIK, Petra KRHOVSKA, Jakub RADOCHA, Lenka POSPISILOVA, Lucie KUBÍNOVÁ, Jiří JARKOVSKÝ, Ivan SPICKA, Jan STRAUB, Petr PAVLICEK, Alexandra JUNGOVA, Tomas JELINEK, Viera SANDECKÁ, Vladimir MAISNAR, Roman HAJEK and Luděk POUR. Identification of patients at high risk of secondary extramedullary multiple myeloma development. \textit{British journal of haematology}. England: Wiley-Blackwell, 2022, vol.~196, No~4, p.~954-962. ISSN~0007-1048. Available from: https://dx.doi.org/10.1111/bjh.17925.

Detailed Information on Publication Record